Status:
COMPLETED
BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19
Lead Sponsor:
Ivano-Frankivsk National Medical University
Conditions:
Covid19
Nasopharyngitis
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
According to WHO (World Health Organisation) data, about 40% of patients with COVID-19 (Corona Virus SARS-CoV-2) have a mild course of the disease, namely, cases of mild course are of great danger fro...
Detailed Description
The new coronavirus (2019-nCoV) from Wuhan is currently of great concern, as the virus is spreading rapidly around the world and the number of cases and deaths is constantly growing. The main cause of...
Eligibility Criteria
Inclusion
- Age 18-70 years old;
- Clinical signs of a mild form of COVID-19 (acute nasopharyngitis associated with 2019-nCoV), assessed by direct contact or remotely: sudden onset, fever, cough
- \+ at least one of the following:
- nasal congestion;
- discharge from the nose (front and back rhinorrhea);
- anosmia/hyposmia;
- Contact with a confirmed or suspected case of COVID-19
- The possibility of treatment on an outpatient basis subject to the self-isolation mode
Exclusion
- Indications for inpatient treatment
- The presence of immunodeficiency conditions, oncological diseases, chronic diseases of the cardiovascular or broncho-pulmonary system, diabetes mellitus.
- Individual intolerance to the components of the drug.
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 8 2021
Estimated Enrollment :
133 Patients enrolled
Trial Details
Trial ID
NCT04797936
Start Date
May 1 2020
End Date
January 8 2021
Last Update
March 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ivano-Frankivsk National Medical University
Ivano-Frankivsk, Ukraine, 76000